Michael M. Gottesman

65.0k total citations · 20 hit papers
408 papers, 53.6k citations indexed

About

Michael M. Gottesman is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Michael M. Gottesman has authored 408 papers receiving a total of 53.6k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Molecular Biology, 239 papers in Oncology and 51 papers in Infectious Diseases. Recurrent topics in Michael M. Gottesman's work include Drug Transport and Resistance Mechanisms (215 papers), RNA Interference and Gene Delivery (61 papers) and Cancer therapeutics and mechanisms (53 papers). Michael M. Gottesman is often cited by papers focused on Drug Transport and Resistance Mechanisms (215 papers), RNA Interference and Gene Delivery (61 papers) and Cancer therapeutics and mechanisms (53 papers). Michael M. Gottesman collaborates with scholars based in United States, Japan and Israel. Michael M. Gottesman's co-authors include Ira Pastan, Susan E. Bates, Suresh V. Ambudkar, Tito Fojo, Kazumitsu Ueda, I Pastan, Matthew D. Hall, Antonio Tito Fojo, Gergely Szakács and Chava Kimchi‐Sarfaty and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Michael M. Gottesman

403 papers receiving 52.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multidrug resistance in cancer: role of ATP–dependent transporters

2002 4.5k citations Michael M. Gottesman, Susan E. Bates et al. Nature reviews. Cancer profile →
Targeting multidrug resistance in cancer

2006 3.0k citations Gergely Szakács, Joseph A. Ludwig et al. profile →
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

1987 2.3k citations Michael M. Gottesman et al. Proceedings of the National Academy of Sciences profile →
Mechanisms of Cancer Drug Resistance

2002 2.2k citations Michael M. Gottesman profile →
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity

2006 1.9k citations Chava Kimchi‐Sarfaty, Jung Mi Oh et al. Science profile →
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER

1999 1.7k citations Suresh V. Ambudkar, Michael M. Gottesman et al. profile →
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells

1986 1.7k citations Michael M. Gottesman et al. profile →
Revisiting the role of ABC transporters in multidrug-resistant cancer

2018 1.4k citations Robert W. Robey, Kristen M. Pluchino et al. Nature reviews. Cancer profile →
Expression of a multidrug-resistance gene in human tumors and tissues.

1987 1.3k citations Antonio Tito Fojo, Michael M. Gottesman et al. Proceedings of the National Academy of Sciences profile →
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.

1987 919 citations Michael M. Gottesman et al. Proceedings of the National Academy of Sciences profile →
P-glycoprotein: from genomics to mechanism

2003 873 citations Suresh V. Ambudkar, Chava Kimchi‐Sarfaty et al. profile →
Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes

2012 751 citations Ding‐Wu Shen, Lynn M. Pouliot et al. profile →
The multidrug transporter, a double-edged sword.

1988 659 citations Michael M. Gottesman et al. profile →
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53

1992 630 citations Michael M. Gottesman et al. Science profile →
Multiple-Drug Resistance in Human Cancer

1987 605 citations Michael M. Gottesman et al. profile →
Mechanisms of Multidrug Resistance in Cancer

2009 569 citations Michael M. Gottesman et al. profile →
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

1986 558 citations Antonio Tito Fojo, Michael M. Gottesman et al. Proceedings of the National Academy of Sciences profile →
Human Multidrug-Resistant Cell Lines: Increased mdr 1 Expression Can Precede Gene Amplification

1986 528 citations Antonio Tito Fojo, Michael M. Gottesman et al. Science profile →
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs

1985 476 citations Antonio Tito Fojo, Michael M. Gottesman et al. profile →
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells.

1988 419 citations Michael M. Gottesman et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Michael M. Gottesman

Since Specialization

Citations

This map shows the geographic impact of Michael M. Gottesman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael M. Gottesman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael M. Gottesman more than expected).

Fields of papers citing papers by Michael M. Gottesman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael M. Gottesman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael M. Gottesman. The network helps show where Michael M. Gottesman may publish in the future.

Co-authorship network of co-authors of Michael M. Gottesman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael M. Gottesman. A scholar is included among the top collaborators of Michael M. Gottesman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael M. Gottesman. Michael M. Gottesman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Resistance signatures manifested in early drug response across cancer types and species 2025 ·Cancer Drug Resistance ·(unknown), (unknown), (unknown), (unknown), (unknown), Michael M. Gottesman, Sridhar Hannenhalli	0
2	Progress in characterizing ABC multidrug transporters in zebrafish 2023 ·Drug Resistance Updates ·(unknown), (unknown), Robert W. Robey, Michael M. Gottesman	5
3	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein 2019 ·Molecular Pharmacology ·Tobie D. Lee, Olivia W. Lee, Kyle R. Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, (unknown), Carleen Klumpp‐Thomas, Robert W. Robey, Suresh V. Ambudkar, Min Shen, Michael M. Gottesman, Matthew D. Hall	22
4	Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale 2019 ·Journal of Medicinal Chemistry ·Lyn M. Huff, Sachi Horibata, Robert W. Robey, Matthew D. Hall, Michael M. Gottesman	5
5	Revisiting the role of ABC transporters in multidrug-resistant cancer breakdown → 2018 ·Nature reviews. Cancer ·Robert W. Robey, Kristen M. Pluchino, Matthew D. Hall, Antonio Tito Fojo, Susan E. Bates, Michael M. Gottesman	1382
6	Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response 2016 ·Cancer Research ·James M. Greene, Doron Levy, (unknown), Michael M. Gottesman, Orit Lavi	19
7	Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes 2014 ·Cancer Research ·Matthew D. Hall, Katherine A. Telma, (unknown), Tobie D. Lee, James P. Madigan, John R. Lloyd, Ian S. Goldlust, James D. Hoeschele, Michael M. Gottesman	293
8	The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity 2014 ·Molecular Cancer Therapeutics ·(unknown), Bih‐Rong Wei, James P. Madigan, Matthew D. Hall, Richard J. Simpson, Zhengping Zhuang, Michael M. Gottesman	39
9	The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance 2013 ·Cancer Research ·Orit Lavi, James M. Greene, Doron Levy, Michael M. Gottesman	48
10	MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer 2013 ·Cancer Research ·King Leung Fung, James Pan, Shinobu Ohnuma, Paul E. Lund, (unknown), Chava Kimchi‐Sarfaty, Suresh V. Ambudkar, Michael M. Gottesman	96
11	Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family 2012 ·Cancer Research ·Lynn M. Pouliot, Yu‐Chi Chen, (unknown), Rajarshi Guha, Scott E. Martin, Michael M. Gottesman, Matthew D. Hall	84
12	Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma 2012 ·Clinical Cancer Research ·Jean-Pierre Gillet, Anna Maria Calcagno, Sudhir Varma, Ben Davidson, Mari Bunkholt Elstrand, Ram Ganapathi, Aparna A. Kamat, Anil K. Sood, Suresh V. Ambudkar, Michael V. Seiden, Bo R. Rueda, Michael M. Gottesman	40
13	Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells 2009 ·Cancer Research ·Dóra Türk, Matthew D. Hall, Benjamin F. Chu, Joseph A. Ludwig, Henry M. Fales, Michael M. Gottesman, Gergely Szakács	87
14	Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database 2009 ·Molecular Cancer Therapeutics ·Josiah N. Orina, Anna Maria Calcagno, Chung‐Pu Wu, Sudhir Varma, Joanna H. Shih, Min Lin, Gabriel S. Eichler, John N. Weinstein, Yves Pommier, Suresh V. Ambudkar, Michael M. Gottesman, Jean-Pierre Gillet	31
15	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters 2008 ·Molecular Cancer Therapeutics ·Mitsunori Okabe, Gergely Szakács, Mark A. Reimers, Toshihiro Suzuki, Matthew D. Hall, Takaaki Abe, John N. Weinstein, Michael M. Gottesman	124
16	Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer 2007 ·Cancer Research ·Zuben E. Sauna, Chava Kimchi‐Sarfaty, Suresh V. Ambudkar, Michael M. Gottesman	194
17	A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity breakdown → 2006 ·Science ·Chava Kimchi‐Sarfaty, Jung Mi Oh, In‐Wha Kim, Zuben E. Sauna, Anna Maria Calcagno, Suresh V. Ambudkar, Michael M. Gottesman	1912
18	Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas 2006 ·Proceedings of the National Academy of Sciences ·Kevin G. Chen, Julio C. Valencia, Barry Lai, Guofeng Zhang, (unknown), François Rouzaud, Werner Berens, Stephen Wincovitch, Susan H. Garfield, Richard D. Leapman, Vincent J. Hearing, Michael M. Gottesman	141
19	Localization of Alexa-conjugated cisplatin in cisplatin-resistant cell lines 2004 ·Cancer Research ·Xing‐Jie Liang, Ding‐Wu Shen, Stephen Wincovitch, Susan H. Garfield, Michael M. Gottesman	1
20	Molecular genetics of mammalian cells 1987 ·Academic Press eBooks ·Michael M. Gottesman	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact